Bioterror “Strategic Investor” Initiative Must Be Resolved As House, Senate Pass Dueling Bills
This article was originally published in The Pink Sheet Daily
House- and Senate-passed bills reauthorizing the 2006 Pandemic and All-Hazards Preparedness Act are similar in many respects in their efforts to accelerate medical countermeasure development. However, the House bill lacks a Senate provision that would allow HHS to contract with a non-profit entity to invest in companies developing countermeasures.
You may also be interested in...
Chimerix CEO tells Congress allocating Project Bioshield a multi-year funding stream would provide more long-term certainty for countermeasure sponsors.
With priority review voucher values falling, Congress may want to think about additional incentives for medical countermeasure development, Commissioner Gottlieb tells Senate committee.
ADUFA reauthorization may become the vehicle to move track and trace and compounding legislation. Reimbursement changes to mitigate shortages appear less likely.